Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Future Med Chem ; 16(2): 139-155, 2024 01.
Article in English | MEDLINE | ID: mdl-38131191

ABSTRACT

Aim: The assessment of the antileishmanial potential of 22 vanillin-containing 1,2,3-triazole derivatives against Leishmania braziliensis is reported. Materials & methods: Initial screening was performed against the parasite promastigote form. The most active compound, 4b, targeted parasites within amastigotes (IC50 = 4.2 ± 1.0 µmol l-1), presenting low cytotoxicity and a selective index value of 39. 4D quantitative structure-activity relationship and molecular docking studies provided insights into structure-activity and biological effects. Conclusion: A vanillin derivative with significant antileishmanial activity was identified. Enhanced activity was linked to increased electrostatic and Van der Waals interactions near the benzyl ring of the derivatives. Molecular docking indicated the inhibition of the Leishmania amazonensis sterol 14α-demethylase, using Leishmania infantum sterol 14α-demethylase as a model, without affecting the human isoform. Inhibition was active site competition with lanosterol.


Subject(s)
Antiprotozoal Agents , Benzaldehydes , Quantitative Structure-Activity Relationship , Humans , Molecular Docking Simulation , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/chemistry , Triazoles/pharmacology , Sterols , Structure-Activity Relationship
2.
Exp Parasitol ; 238: 108269, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35526574

ABSTRACT

Leishmaniasis is a group of neglected vector-borne tropical diseases caused by protozoan parasites of the genus Leishmania that multiply within phagocytic cells and have a wide range of clinical manifestations. Cutaneous leishmaniasis (CL) is a serious public health that affects more than 98 countries, putting 350 million people at risk. There are no vaccines that have been proven to prevent CL, and the treatment relies on drugs that often have severe side effects, justifying the search for new antileishmanial treatments. In the present investigation, it is demonstrated that 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methylbenzyl)-1H-1,2,3-triazole (7k) presents significant antileishmanial activity (IC50 of 7.4 µmol L-1 and 1.6 µmol L-1 for promastigote and amastigote forms, respectively), low cytotoxicity against macrophage cells (IC50 of 211.9 µmol L-1), and a selective index of 132.5. Under similar conditions, compound 7k outperformed glucantime and pentamidine, two commonly used drugs in clinics. In vivo assays on CL-infected female BALB/c mice demonstrated that compound 7k had activity similar to intralesional glucantime when administered orally, with decreased lesion and parasitic load, and a low systemic toxic effect. Given the importance of understanding the relationship between compound structure and biological activity in the research and development of new drugs, the development of a quantitative structure-activity relationship (QSAR) model for the leishmanicidal activity presented by the eugenol derivatives with 1,2,3-triazole functionalities is also described herein. This study demonstrates the therapeutic potential of orally active eugenol derivatives against CL and provides useful insights into the relationship between the chemical structures of triazolic eugenol derivatives and their biological profile.


Subject(s)
Antiprotozoal Agents , Leishmaniasis, Cutaneous , Leishmaniasis , Animals , Antiprotozoal Agents/therapeutic use , Antiprotozoal Agents/toxicity , Eugenol/pharmacology , Eugenol/therapeutic use , Female , Humans , Leishmaniasis/drug therapy , Leishmaniasis, Cutaneous/drug therapy , Meglumine Antimoniate/therapeutic use , Mice , Quantitative Structure-Activity Relationship , Structure-Activity Relationship , Triazoles/pharmacology , Triazoles/therapeutic use
3.
Eur J Med Chem ; 45(10): 4562-9, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20696502

ABSTRACT

A quantitative structure-activity relationship (QSAR) study of twenty flavonoid derivatives with antimutagenic activity against 3-nitrofluoranthene (3-NFA) was performed by Partial Least Squares (PLS), using Ordered Predictors Selection (OPS) algorithm for variable selection. Four descriptors (PJI2, Mor27m, G1e and R4u+) were selected and a good model (n = 19; R(2) = 0.747; SEC = 0.332; PRESS(cal) = 1.768; F((2,27)) = 23.585; Q(LOO)(2) = 0.590; SEV = 0.388; PRESS(val) = 2.858; R(pred)(2) = 0.591; SEP = 0.394; ARE(pred) = 5.230%; k = 1.005; k' = 0.990; |R(02) - R'(02)| = 0.109) was built with two latent variables describing 83.410% of the original information. Leave-N-out cross validation (LNO) and y-randomization were performed in order to confirm the robustness of the model. The topological descriptors selected indicate that the antimutagenic activity against 3-NFA depends on molecular size, shape and Sanderson electronegativity of flavonoids. The proposed model may provide a better understanding of the antimutagenic activity of flavonoids and can be used as a guidance for proposition of new chemopreventive agents.


Subject(s)
Antimutagenic Agents/chemistry , Antimutagenic Agents/pharmacology , Flavonoids/chemistry , Flavonoids/pharmacology , Fluorenes/adverse effects , Mutagens/adverse effects , Salmonella typhimurium/drug effects , Algorithms , Fluorenes/metabolism , Least-Squares Analysis , Models, Biological , Models, Molecular , Mutagens/metabolism , Quantitative Structure-Activity Relationship , Salmonella typhimurium/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...